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This year’s International Society for Stem Cell Research (ISSCR) annual meeting was an opportunity for
attendees to be inspired by early successes, to grapple with the challenges of applying emerging technolo-
gies, and to contemplate moving with increasing but cautious optimism toward the clinic.The 2011 ISSCR Annual Meeting was held in Toronto, Canada,
under the auspices of the Annual Meeting Program Committee
chaired by Haifan Lin (Yale University School of Medicine). This
year’s gathering had an upbeat and inspirational feel that was fu-
eled by a presidential session that looked back on early
successes of the society, recounted recent scientific develop-
ments, and described fledgling steps toward the clinic for new
stem cell treatments. Throughout the meeting, one could not
help but feel that palpable progress was being made and that,
in small but ever-increasing increments, the promise of stem
cell research was being realized. The almost motivational nature
of the ISSCR meeting was further ‘‘enhanced’’ by the fitness
professionals and techno beats emanating from the neighboring
body building expo that mingled with the stem cell research
community in the Toronto Convention Center. Altogether, one
was left with the impression that the field of stem cell research
was rapidly maturing and finally ready to take on some heavy
lifting.
Setting the Stage: Past, Present, and Future
Themeeting began in earnest with theWelcome and State of the
Society Address by the outgoing president, Elaine Fuchs. In
addition to documenting the growth and strength of the society,
she described significant new initiatives that would soon be
launched, including an important effort in developing educa-
tional materials. Her address culminated in the presentation of
the ISSCR’s public service award to Robert Klein, outgoing
Chairman of the California Institute of Regenerative Medicine’s
(CIRM’s) Independent Oversight Committee. Klein received the
award in recognition of his instrumental role in the initiation and
passage of Proposition 71, the voter referendum that established
CIRM and led to 3 billion dollars of support for stem cell research
in California. This was indeed a very timely award, because this
year in particular, it was clear that the positive effects of CIRM
support were being felt in earnest. Funding directly from the state
of California was cited as instrumental for the success of many
projects described by speakers at this year’s meeting.
Following the presentation to Klein, Fuchs charged the next
two scientific speakers in her session to look back and provide
a historical perspective on the topics they discussed. This
charge was first taken up by Janet Rossant (Hospital for Sick
Children, Canada), who in her talk provided a wonderful, brief
history of mammalian stem cell research. She first described
Till and McCulloch’s work on the blood-forming stem cell andthen recounted the discovery of pluripotent teratocarcinomas.
She proceeded to explain how the discovery of teratocarci-
nomas led to the derivation of embryonal carcinoma cells and
finally the isolation of the first embryonic stem cell (ESC) lines.
She then went on to share some recent results from her group
that potentially explain why ESCs do not ordinarily contribute
to the primitive endoderm after injection into the blastocyst. In
particular, it was fascinating to hear about the prominent role
played by Canadian scientists in the advancement of the stem
cell field.
Rossant passed the podium on to a former president of the
society, George Daley (Children’s Hospital Boston, USA).
Following her lead, Daley provided a similarly exciting descrip-
tion of the origins of the field of nuclear reprogramming. His
remarks were informative, humorous, and enjoyable. Entertain-
ingly, he ranged from the description of early cloning experi-
ments carried out by John Gurdon and colleagues to the first
successful mammalian cloning experiments, and then culmi-
nated with the development of induced pluripotency by
Katzutoshi Takahashi and Shinya Yamanaka. Daley then went
on to highlight the many opportunities that induced pluripotent
stem cell (iPSC) reprogramming now offers in the area of
in vitro disease modeling.
A major theme of the meeting—that of how to implement
stem-cell-based therapeutic strategies in humans—was set
forth in the Keynote Address by Robert Langer (Massachusetts
Institute of Technology, USA), who discussed the critical role
of bioengineered materials. The successful delivery of com-
pounds, nucleic acids, or even cell products in a controlled
manner requires high-throughput screens to identify variants of
existing scaffolds or combinations of materials that optimize
their physical properties while minimizing immunogenicity. To
this end, a recent study showed that specific lipid derivatives,
when combined, could mediate high-level siRNA-driven knock-
down of gene expression even if each lipid was ineffective alone
(Whitehead et al., 2011).
The push to move novel therapies into the clinic for profit
comes with the risk of premature testing in humans and even
fraudulent claims that an approach is ‘‘proven effective.’’ The
marketing of stem cell therapy before safety and efficacy are
demonstrated is an ongoing issue, which was highlighted by the
ISSCR in 2010 and again this year by Irving Weissman (Stanford
University School of Medicine, USA). Weissman emphasized the
importance of clear nomenclature in establishing an ironcladCell Stem Cell 9, 311–315, October 7, 2011 ª2011 ISSCR 311
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Shinya Yamanaka, M.D., Ph.D., and Kazutoshi Takahashi, Ph.D.,
received the ISSCR McEwen Centre Award for Innovation. Left
to right: Rob McEwen, Fred H. Gage, Cheryl McEwen, Kazutoshi
Takahashi, and Shinya Yamanaka.
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conjunction with transplantation, as employed in the hematopoi-
etic stem cell (HSC) field, he argued, is absolutely required for
a rigorous definition of a stem cell. Weissman laid out a set of
criteria that shouldbe in placebefore a stemcell treatment ismar-
keted or adopted as a standard of care: (1) preclinical proof of
principle, (2) verification of data in independent laboratories, (3)
involvement of a medical ethics committee such as a hospital
institutional reviewboard, to protect the rights of humansubjects,
and (4) approval by an official regulatory body (e.g., by the Food
and Drug Administration).
The 2011 Outstanding Young Investigator Award was pre-
sented to Robert Blelloch (University of California, San
Francisco, USA) who screened for microRNAs (miRNAs) that
influence self-renewal and differentiation. His laboratory identi-
fied ESC-cycle regulating miRNAs (ESCCs) as critical self-
renewal factors for mouse ESCs (Melton et al., 2010). More
recently, he tested the concerted effects of opposing miRNA
families (ESCCs and let-7 miRNAs) on reprogramming in human
iPSCs by influencing pathways related to the mesenchymal to
epithelial transition (MET). His unique approach strongly argues
for the power of probing reprogramming and other complex
phenotypes using a miRNA-based screening strategy.
Germline Stem Cells
Ruth Lehmann (New York University School of Medicine, USA)
discussed how repression is a conserved theme in the restriction
of germ cell fate. The Lehmann laboratory has found that main-
tenance of a germ cell state not only requires suppression of
unwanted host gene expression but also specifically that of
foreign DNA such as transposable elements. This is accom-
plished in the germline by piwi-interacting (pi)RNAs, which
colocalize with H3K9trimethyl marks at piRNA loci (Rangan
et al., 2011).
Azim Surani (University of Cambridge, UK) recounted the
remarkable epigenetic odyssey of germline stem cells in mice,
which experience at least two distinct rounds of reprogramming
in normal development (the first just after fertilization and the
second at embryonic day 7.25). He also discussed a parallel
model of reprogramming, that of reversion of epiblast stem cells312 Cell Stem Cell 9, 311–315, October 7, 2011 ª2011 ISSCRto an ESC-like state (Hayashi and Surani, 2009). An analogous
reprogramming model came from Hans Scho¨ler (Max Planck
Institute for Molecular Biomedicine, Germany), who discussed
reprogramming of postnatal somatic and germ cells, in addition
to epiblast stem cells, and the utility of cell culture to lock the
epigenetic state of the cell (Han et al., 2011).
Stem Cell Niche: Of Vascular Cells and Other
Stem Cell Types
From the hematopoietic system to the germ cell lineage, it is
becoming apparent that endothelial cells can orchestrate a
plethora of functions from stem cell specification tomaintenance
to differentiation. Owen Tamplin (Zon laboratory, Children’s
Hospital Boston, USA) presented data on the birth of the HSC
during zebrafish development. As in the mouse, a subset of
HSCs emerges in intimate association with the vasculature
before migrating to the caudal hematopoietic tissue. This
process appears to depend on lipid signaling and could be
blocked by interfering with the sphingosine-1-phosphate
receptor pathway in HSCs. Elaine Dzierzak (Erasmus Medical
Center, Netherlands) reviewed disparate sites of developmental
hematopoiesis, including development of first HSCs from the
aorta-gonad-mesonephros (AGM), visualized with high-resolu-
tion fluorescence microscopy and with authenticity proven by
transplant (Yokomizo et al., 2011). Interestingly, CD41 was
present on both AGM and yolk sac HSCs, but not in the HSCs
that form later in development (Robin et al., 2011).
Sean Morrison (University of Michigan, USA; recently moved
to University of Texas Southwestern Medical Center, USA)
reviewed the complexity of the niche in adults, comprising a
multicellular environment with potentially overlapping contribu-
tions from different cell types. A good example is stem cell factor
(SCF), which has been suggested to originate from endothelial,
osteoblastic, mesenchymal, and/or uncharacterized stromal
cells in the bone marrow. His major conclusion is that HSCs
reside in a perivascular niche in which endothelial cells and
perivascular stromal cells secrete SCF for HSC maintenance.
His work is the first to use genetic approaches to functionally
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stem cell maintenance in the hematopoietic system. Similarly,
Ronald D. McKay (Lieber Institute for Brain Development, USA)
raised the question of whether neural recovery after injury could
be induced therapeutically by reactivating or enhancing endog-
enous repair mechanisms from within the niche.
Margaret Goodell’s laboratory (Baylor College of Medicine,
USA) has probed the epigenetic regulation of HSCs. Her exper-
iments using serial transplantation of HSCs in mice indicate that
loss of de novo DNA methylation (via methyltransferase gene
deletion) in HSCs results in impairment of differentiation, appar-
ently related to hypomethylation at specific differentially methyl-
ated regions (DMRs) including some previously implicated in
tumorigenesis.
Shosei Yoshida (National Institute for Basic Biology, Japan)
reviewed recent data challenging the dogma that syncytial
spermatogonia in mice are irreversibly committed to differentia-
tion. An evolving view is that the stem cell compartment in the
testis is more dynamic and spermatogonia may revert or dedif-
ferentiate to a stem cell state. Time-lapse video has revealed
that undifferentiated spermatogonia migrate during differentia-
tion away from vascular zones, for which the underlying reasons
have yet to be unraveled.
Emi Nishimura (Tokyo Medical and Dental University, Japan)
discussed the concept that tissue stem cells can themselves
create the niche for other adjacent stem cell types. This fasci-
nating observation is exemplified in the skin, where collagen
XVII expression by hair follicle stem cells is required for mainte-
nance of adjacent melanocyte stem cells by providing TGFb
signaling (Tanimura et al., 2011).
Stem Cell Behavior: Symmetric versus Asymmetric
Cell Divisions
As relayed in a fascinating talk, Scott Williams (Fuchs laboratory,
Rockefeller University, USA) studied regulation of the switch
between symmetric and asymmetric cell divisions during
construction of mammalian skin. Their elegant studies have
employed lentiviral shRNA delivered in utero and have found
that disruption of asymmetric cell division genes caused func-
tional defects in skin differentiation, leading to hyperpermeability
and thinning. These phenotypes were attributable to aberrant
loss of Notch signaling during differentiation (Williams et al.,
2011).
All adult stem cells are not alike, however. This point was
hammered home by Hans Clevers (Hubrecht Institute, Nether-
lands) who described distinct modes of tissue stem cell self-
renewal. Clevers and colleagues have previously shown that,
unlike some other organ sites, intestinal stem cells undergo
symmetric cell divisions followed by stochastic determination
of daughter stem cells, ultimately remaining as such or differen-
tiating (Simons and Clevers, 2011). Using multicolor lineage
tracing, it was shown that each crypt unit becomes monoclonal
on a random basis, consistent with a model for neutral competi-
tion between stem cells. Now, Dr. Clevers’ group has used
compound mutants of LGR4/5 to determine that Wnt signaling,
triggered by R-spondin1, is a critical downstream pathway
(de Lau et al., 2011).
Swathi Yadlapilli (Yamashita laboratory, University of Michi-
gan, USA) asked the provocative question of whetherDrosophilamale germline stem cells (GSCs) retain only a subset of chromo-
somes asymmetrically and used novel techniques to track
segregation of individual chromosomes in vivo. While they did
not find generalized asymmetric segregation of chromosomes
during stem cell division, their novel techniques revealed a
preferential segregation of one strand of the Y chromosome in
GSCs (Yadlapalli et al., 2011).
The functional consequences of stem-cell-like behavior of
tumor cells were discussed by Pier Paolo di Fiore (Instituto
FIRC di Oncologia, Italy). Specifically, the stem-cell-like fraction
of mammary tumors was shown to revert to a pattern of predom-
inantly symmetric cell divisions due to loss of p53, as shown by
partitioning of NUMB to both daughter cells and using a live cell
stain (Pece et al., 2011). By skipping asymmetric cell division, the
tumor is able to acquire bulk and becomes resistant to therapy.
In the same vein, Juergen Knoblich reviewed the pivotal role of
spindle polarity in Drosophila neuroblasts. His laboratory has
shown that disruption of the machinery that maintains polarity
leads to tumor formation (Neumu¨ller et al., 2011).
In his lecture, John Dick (University Health Network, Canada)
touched on two major themes: that of identifying and profiling
single-cell clones of functionally pure human HSCs and how to
model the clonal diversity of cancer stem cells in leukemia. A
major milestone was recently achieved when Dick’s group linked
CD49f expression with human HSCs and achieved long-term
mulitilineage engraftment of single human cells in immune-
compromised mice, using a sorting strategy based on Thy1+
Rhodamine123loCD49f+ (Notta et al., 2011a). In an illuminating
study of the clonality of leukemia, Dr. Dick’s group recently
found, by tracking DNA copy number alterations, that acute
lymphocytic leukemias follow a nonlinear, branching pattern of
evolution. Loss of CDKN2A/B was associated with increased
aggressiveness and competitiveness of leukemia-initiating cells
(Notta et al., 2011b).
Sources of Genetic Variation
Alysson Muotri (University of California, San Diego, USA) had
previously showed increased de novo L1 retrotransposition
insertions in iPSC-derived neurons fromRett Syndrome patients.
His laboratory recently found that common defects in neuronal
function were observed in iPSC-derived neurons from Rett
Syndrome patients and other autism spectrum disorder patients
(Marchetto et al., 2010). Michael McConnell (Salk Institute, USA)
provided a succinct review of both known and unconventional
sources of interindividual genetic variation. He is employing
novel, single-cell-based approaches to quantify mosaicism in
the brain.
An understanding of somatic mosaicism is highly relevant to
the future prospects of iPSC-based therapy, because a similar
and perhaps more robust phenomenon occurs in cultured
cells. Athurva Gore (University of California, San Diego, USA)
described a study revealing substantial genetic variation that
arises as a consequence of selection and cloning of primary cells
in culture and also generation of iPSCs. Similarly, Uri Ben-David
(The HebrewUniversity, Israel) discussed the incidence of karyo-
typic abnormalities in human iPSCs and derivative cells lines.
Such aneuploidy apparently can arise either from preexisting
defects in the parental cells or from de novo events during
subsequent culture (Mayshar et al., 2010).Cell Stem Cell 9, 311–315, October 7, 2011 ª2011 ISSCR 313
Cell Stem Cell
ISSCR: Meeting ReportAging
With the goal of rejuvenating agingmuscle, Irina Conboy (Univer-
sity of California, Berkeley) related how stem-cell-driven regen-
erative capacity is highly dependent on environmental or
niche-derived factors (Conboy et al., 2011). She hypothesized
that muscle stem cells remain young while the surrounding niche
ages. This theme was also raised by Amy Wagers (Harvard
University, USA), who described the potential for cultured
muscle satellite cells as a tool in the discovery of new bioactive
molecules for muscle diseases (Shadrach and Wagers, 2011).
The biochemical modulation of transcription factor activity in
muscle satellite cell differentiation was discussed by Michael
Rudnicki (Ottawa Hospital Research Institute, Canada).
Reprogramming
A novel application for iPSCs described at the meeting is the
modeling of autoinflammatory disorders. This strategywas taken
by Takayuki Tanaka and colleagues (Kyoto University, Japan)
who found that a substantial fraction of chronic infantile neuro-
logical cutaneous and articular syndrome (CINCA) cases are
due to somatic mosaic NLRP3 mutations, leading to both cell-
autonomous and non-cell-autonomousmacrophage-dependent
effects in a dominant manner (Tanaka et al., 2011).
Shinya Yamanaka (Kyoto University, Japan) presented work
from his laboratory, which continues to refine the reprogramming
technology he developed. Although induction of pluripotency is
most efficient when cMyc is used, the resulting cells have
substantial, persistent oncogenic potential, even after their
differentiation. To overcome this problem, his laboratory consid-
ered factors that were involved in early reprogramming events in
the embryo. In the course of those studies, they discovered that
the factor Glis1 compensates very effectively for cMyc, and
without the oncogenic side-effects (Maekawa et al., 2011). In
this way, his studies argue that continued study of the early
embryo will help improve the safety and efficiency of reprogram-
ming technologies.
Building the Road to the Clinic
Although all present were galvanized by the rapid progress in
stem cell science that was reported at this year’s meeting, the
important and weighty task of beginning to move these findings
in a more translational direction was on the minds of many
participants. The importance of continuing to focus on the fulfill-
ment of the clinical promise of stem cell research was reinforced
by a deeply moving presentation from eloquent patient advo-
cate and journalist Charles Sabine. In an instant, the audience
was transported from the shoes of the bench researcher to
those of the patient or the family member who is attempting to
grapple with the unthinkable reality of a terminal illness, such
as Huntington’s disease. At a meeting brimming with excep-
tional science and the promise of new clinical strategies, it
was not only humbling and sobering but also inspiring to hear
the grace and resolve he has marshaled against difficult if not
impossible circumstances. In particular, he spoke of the impor-
tance of hope in the lives of those struggling with disease.
Inspiringly, he charged the stem cell community with doing all
that it could to help maintain the hope of people like himself.
Hopefully, Sabine and patient advocates like him will be encour-
aged by the metered but consistent advance of stem cell tech-314 Cell Stem Cell 9, 311–315, October 7, 2011 ª2011 ISSCRnologies toward the clinic that were reported at this year’s
meeting.
This year, some of the most exciting progress continued to be
in the development of new therapies for those suffering from
disease- or injury-related blindness. Notably, Michele De Luca
(University of Milan, Italy) described progress that he and collab-
orator Graziella Pellegrini have made in the area of delivering
autologous limbal stem cells to treat corneal degeneration
following ocular burns. Cultured, autologous limbal cells are
surgically implanted back into the limbus of the patient’s
damaged eye. This year, he reported the results from clinical
studies of 112 such transplants. Remarkably, in more than
75% of cases, corneal regeneration was restored and stable
for as much as 10 years, attributed to p63+ holoclones observed
in the limbal outgrowths (Rama et al., 2010).
A promising and proximal application of human ESCs is in the
treatment of macular degeneration. Peter Coffey (University
College London, UK) described his progress toward delivering
a therapy for macular degeneration based on transplantation of
human ESC-derived pigmented retinal epithelial cells. His team
has been carrying out promising preclinical trials in rat models.
In addition, he unveiled an exciting new surgical procedure
that might be used to deliver the cells in a noninvasive manner
that should result in an outpatient treatment. If pluripotent stem
cells, either iPSCs or ESCs, are ever going to become viable
therapies on a large scale, then it will be critical to be able to
grow and differentiate them on a massive scale. Peter Zandstra
(University of Toronto, Canada) described his lab’s efforts
to overcome this roadblock between basic science and the
clinic. Remarkably, he showed that it might be possible to
grow large volumes of pluripotent stem cell lines in suspension
and even differentiate them ‘‘in line’’ without taking them out of
suspension.
Christopher Breuer (Yale University School of Medicine, USA)
described early clinical trials of a tissue-engineered vascular
graft for the treatment of congenital heart defects, reiterating
the need to transfer knowledge back to the laboratory to
enhance the clinical strategy. He described the identification of
macrophages as both the culprit in stenosis, a complication
seen in a number of patients, and the driver of neovessel forma-
tion, a result that raises an approach using a cell-free biomimetic
scaffold to enhance the innate regenerative mechanisms while
minimizing the risk of occlusion (Hibino et al., 2011).
Deserved Recognition and Parting Thoughts
The final afternoon plenary session was punctuated by the
presentation of a new award, the McEwen Centre Award for
Innovation. No one could possibly debate the worthiness of
this year’s winners: Kazutoshi Takahashi and Shinya Yamanaka
of Kyoto University, Japan for their development of methods
for inducing pluripotency and the resulting effect that their
method is beginning to have on the development of new
cellular models of disease. Particularly moving were the words
of Takahashi during his acknowledgment. He began in a char-
acteristically understated way by saying, ‘‘I don’t see what the
big deal is. I just did a transduction,’’ before, more emotionally,
confessing, ‘‘But seriously, these factors, they reprogrammed
my life.’’ It was a moving moment and a sentiment that was
likely shared by many in the audience. There can be no doubt
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stem cell research and developmental biology, with far-reach-
ing consequences for medicine, perhaps in ways we do not
yet even imagine.
The heartfelt remarks of Takahashi were then followed by a
rousing session that focused on the regulator networks that
govern stemcell behavior. In this sessionRickYoung (Massachu-
setts Institute of Technology, USA) and Stuart Orkin (Children’s
Hospital Boston, USA) described the identification of mecha-
nisms that regulate the switch between self-renewal and
differentiation in pluripotent stem cells, while Judy Lieberman
(Harvard Medical School, USA) conveyed the results of a recent
genome-wide siRNA screen she had performed to identify
inhibitors of breast-cancer-tumor-initiating cells. This session
was capped by the Anne McLaren Memorial Lecture, delivered
by Nicole Le Douarin (Acadamie Des Sciences, France). In her
talk, she outlined experiments carried out by her lab aimed at
studying the properties of the neural crest. In these elegant
studies, which relied heavily on approaches such as the genera-
tion of quail-chick chimeras, she showed that a large proportion
of neural crest progenitors are multipotent stem cells with the
capacity to differentiate down neural, melanocytic, and osteo-
cytic lineages.
The recognition of Takahashi and Yamanaka from Kyoto,
Japan in the final session was also a fitting close for the gath-
ering, dovetailing nicely into the 2012 Annual Meeting, when
the society will once again convene on the eastern edge of
the pacific rim: the Pacifico Yokohama Convention Center in
Yokohama, Japan. When the society gathers again, we are
sure to hear more about how stem cells are changing the face
of science, our understanding of disease, and the development
of new therapeutics.
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